PMID- 30009715
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20211204
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Linking)
VI  - 20
IP  - 1
DP  - 2020
TI  - Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in 
      Naive Difficult to Treat HCV Patients.
PG  - 43-48
LID - 10.2174/1871526518666180716141806 [doi]
AB  - BACKGROUND: Chronic infection with Hepatitis C virus (HCV) is considered as a 
      major cause for developing liver cirrhosis and hepatocellular carcinoma. A new 
      era in HCV treatment is ongoing using Direct Acting Antiviral activity (DAA). The 
      first approved DAA drug was Sofosbuvir which has a high tolerability and 
      preferable pharmacokinetic profile. Another recently developed drug is 
      Daclatasvir a first-in-class HCV NS5A replication complex inhibitor. Both drugs 
      are administered orally once daily and have potent antiviral activity with wide 
      genotypic coverage. METHODS: In the outpatient clinic, one hundred and fifty 
      naive difficult to treat chronic HCV patients were recruited from Tropical 
      Medicine Department at Fayoum public hospital. A combination of Daclatasvir (60 
      mg) and Sofosbuvir (400 mg) (DCV/SOF) has been administered for those patients 
      once daily with Ribavirin (1200 mg or 1000 mg based on patients' weight on two 
      divided doses) over a period of 12 weeks. All patients have been followed up for 
      clinical, laboratory assessment and HCV PCR to detect the efficacy and safety of 
      the therapy. RESULTS: Sustained Virologic Response rate (SVR12) was achieved in 
      the vast majority of patients (90.67%). Cirrhotic patients showed lower SVR 
      compared to non-cirrhotic patients (88.89% vs 90.91%, respectively). Around half 
      of the patients (49.33%) developed adverse events (AEs) during treatment. The 
      most common AEs were headache, fatigue and abdominal pain. CONCLUSION: The 
      available evidence seems to suggest that combination therapy of (DCV/SOF with 
      RBV) in the treatment of chronic HCV genotype IV naive difficult to treat 
      patients either cirrhotic or non-cirrhotic is safe and effective. Monitoring for 
      clinical and laboratory hepatic parameters was the basis for these findings.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Wahsh, Engy A
AU  - Wahsh EA
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Nahda University, Beni 
      Suef, Egypt.
FAU - Hussein, Amal K
AU  - Hussein AK
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Minia University, 
      Minia, Egypt.
FAU - Gomaa, Ahmed A
AU  - Gomaa AA
AD  - Department of Tropical Medicine, Faculty of Medicine, Fayoum University, Fayoum, 
      Egypt.
FAU - Baraka, Mohamed A
AU  - Baraka MA
AD  - Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, 
      United Arab Emirates.
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman 
      Bin Faisal University (University of Dammam), Saudi Arabia.
FAU - Al-Deen Abead, Mohie
AU  - Al-Deen Abead M
AD  - Department of Biochemistry, Egyptian Ministry of Interior, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - 0 (Carbamates)
RN  - 0 (Drug Combinations)
RN  - 0 (Imidazoles)
RN  - 0 (Pyrrolidines)
RN  - 49717AWG6K (Ribavirin)
RN  - HG18B9YRS7 (Valine)
RN  - LI2427F9CI (daclatasvir)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Carbamates
MH  - Case-Control Studies
MH  - Drug Combinations
MH  - Egypt
MH  - Female
MH  - Hepacivirus/drug effects/growth & development
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Imidazoles/*administration & dosage/adverse effects
MH  - Liver Cirrhosis/drug therapy/*virology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pyrrolidines
MH  - Ribavirin/*administration & dosage/adverse effects
MH  - Sofosbuvir/*administration & dosage/adverse effects
MH  - Sustained Virologic Response
MH  - Treatment Outcome
MH  - Valine/analogs & derivatives
MH  - Viral Load/drug effects
OTO - NOTNLM
OT  - Chronic hepatitis C
OT  - daclatasvir
OT  - difficult to treat
OT  - hepatocellular carcinoma
OT  - inhibitor
OT  - ribavirin
OT  - sofosbuvir.
EDAT- 2018/07/17 06:00
MHDA- 2020/10/08 06:00
CRDT- 2018/07/17 06:00
PHST- 2018/03/04 00:00 [received]
PHST- 2018/07/09 00:00 [revised]
PHST- 2018/07/10 00:00 [accepted]
PHST- 2018/07/17 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
PHST- 2018/07/17 06:00 [entrez]
AID - IDDT-EPUB-91729 [pii]
AID - 10.2174/1871526518666180716141806 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2020;20(1):43-48. doi: 
      10.2174/1871526518666180716141806.